Rare Scalp Reaction Discovered in Lung Cancer Patient Treated with Amivantamab Following Radiotherapy
Amivantamab, a bispecific monoclonal antibody designed to target both epidermal growth factor receptor (EGFR) and mesenchymal-epithelial transition factor (MET), has rapidly transformed the therapeutic landscape for patients with EGFR-mutant non-small cell...
Read moreDetails























